Loading...
•
Jun 30
Tyra Biosciences Q2 2025 Earnings Report
Tyra Biosciences reported a net loss in Q2 2025 with continued investment in research and development and no revenue.
Key Takeaways
In Q2 2025, Tyra Biosciences posted a net loss of $18.1 million with no revenue, reflecting ongoing investment in its clinical-stage precision oncology programs. R&D expenses totaled $14.4 million, and the company maintained a strong cash position of $275.1 million.
No revenue reported during Q2 2025.
Net loss totaled $18.1 million, or $0.44 per share.
Research and development expenses were $14.4 million for the quarter.
Cash, cash equivalents, and marketable securities stood at $275.1 million as of June 30, 2025.
Tyra Biosciences
Tyra Biosciences
Forward Guidance
Tyra Biosciences will continue progressing its clinical oncology programs with a focus on TYRA-300 and expects cash reserves to support operations into 2027.
Positive Outlook
- Strong cash position of $275.1 million provides runway into 2027.
- Advancement of TYRA-300 into new clinical trial cohorts.
- Progress on TYRA-200 and TYRA-4303 programs.
- Ongoing patient enrollment in SURF301 Phase 1/2 study.
- Company maintains focus on precision oncology drug development.
Challenges Ahead
- No revenue generated as company remains in clinical development stage.
- Continued net losses quarter over quarter.
- High R&D and G&A expenditures impacting profitability.
- Reliance on future regulatory approvals for clinical assets.
- Potential delays in trial progression or data readouts.